Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Costs and expenses: | ||||
| Cost of goods sold | 12,512 | 11,898 | 23,086 | 20,626 |
| Research and development | 10,669 | 8,055 | 19,452 | 15,808 |
| Selling, general and administrative | 61,035 | 44,393 | 114,179 | 88,411 |
| Amortization of intangible assets | 2,711 | 2,711 | 5,421 | 5,421 |
| Total costs and expenses | 86,927 | 67,057 | 162,138 | 130,266 |
| Income from operations | 5,173 | 4,482 | 13,089 | 1,392 |
| Other income (expense): |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s SG&A?
- Xeris Biopharma Holdings, Inc. (XERS) reported SG&A of $61.04M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s SG&A changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s SG&A increased by 37.5% year-over-year, from $44.39M to $61.04M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s SG&A has grown at a 9.7% compound annual growth rate (CAGR), from $125.72M to $182.37M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Xeris Biopharma Holdings, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude